⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REGN News
Regeneron Pharmaceuticals Inc
Dupilumab Improves Outcomes for EoG in Phase 2 Clinical Trial
prnewswire.com
REGN
SNY
From Vaccines to Therapeutics; How Biotech Is Addressing the Ebola Outbreak Ready to Announce with Confidence?
newsfilecorp.com
SNGX
AEMD
REGN
MRNA
Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
globenewswire.com
REGN
IgA Nephropathy Clinical Trial Space Intensifies with 25+ Companies in Active Development | DelveInsight
globenewswire.com
NVS
VRTX
BIIB
VTRS
AZN
IONS
TAK
ARWR
BHVN
NVO
LLY
LXRX
XRTX
REGN
FMS
MDT
AMPH
DRCT
BMRC
MAZE
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight
prnewswire.com
SNY
JSPR
IFRX
REGN
NVS
NVIDIA Announces BioNeMo Agent Toolkit — Tools for Agents to Accelerate Scientific Discovery
globenewswire.com
NVDA
LRCX
AMAT
SNOW
CDNS
MRVL
MU
SMCI
AMD
INTC
QCOM
GOOG
MSFT
AMZN
LLY
NTRS
REGN
GILD
BMY
PFE
MRNA
BIIB
VRTX
CRSP
EXAS
ROST
DSY
TMO
Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda
globenewswire.com
ABBV
ALNY
ASTL
AZN
BIIB
BMY
CSL
LLY
GILD
GSK
MRK
NVS
NVO
PFE
REGN
SNY
SUN
TEVA
UPST
VRTX
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight
globenewswire.com
BIIB
AMGN
BMY
IMVT
AZN
MRK
CTNT
REGN
GILD
Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)
globenewswire.com
REGN
Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape
globenewswire.com
KODK
RKDA
OTLK
UTHR
CLSD
AZN
BTE
CCNE
IONS
APLS
GYRO
NVS
GNTX
BLTE
JNJ
LCTX
ABBV
REGN